Criteria
2019 European League Against Rheumatism/American College of Rheumatology classification system[1]
Entry criterion
Antinuclear antibodies (ANA) at a titer of ≥1:80 on HEp-2 cells or an equivalent positive test (ever)
If absent, do not classify as SLE; if present, apply additive criteria
Additive criteria
Additive criterion should not be counted if there is a more likely explanation than SLE
Occurrence of a criterion on at least one occasion is sufficient
SLE classification requires at least one clinical criterion and ≥10 points
Criteria need not occur simultaneously
Within each domain, only the highest criterion is counted toward the score*
Clinical domains and criteria
Constitutional
Fever, 2 points
Hematologic
Leukopenia, 3 points
Thrombocytopenia, 4 points
Autoimmune hemolysis, 4 points
Neuropsychiatric
Delirium, 2 points
Psychosis, 3 points
Seizure, 5 points
Mucocutaneous
Nonscarring alopecia, 2 points
Oral ulcers, 2 points
Subacute cutaneous OR discoid lupus, 4 points
Acute cutaneous lupus, 6 points
Serosal
Pleural or pericardial effusion, 5 points
Acute pericarditis, 6 points
Musculoskeletal
Joint involvement, 6 points
Renal
Proteinuria >0.5 g/24 hours, 4 points
Renal biopsy class II or V lupus nephritis, 8 points
Renal biopsy class III or IV lupus nephritis, 10 points
Immunology domains and criteria
Antiphospholipid antibodies
Anticardiolipin antibodies OR anti-beta2-glycoprotein 1 antibodies OR lupus anticoagulant, 2 points
Complement proteins
Low C3 OR low C4, 3 points
Low C3 AND low C4, 4 points
SLE-specific antibodies
Anti-double-stranded (ds)DNA antibody** OR anti-Smith antibody, 6 points
Total score
Scores of 10 or more are classified as systemic lupus erythematosus if the entry criterion has been fulfilled.
* Additional criteria items within the same domain will not be counted.
** In an assay with ≥90% specificity against relevant disease controls.
1997 update of the 1982 American College of Rheumatology revised criteria for the classification of SLE[2][3]
These criteria were initially developed to identify patients for clinical studies and were based on a white population. Any ≥4 of the 11 criteria are required to classify a patient as having SLE. These criteria can be present serially or simultaneously during any interval of observation.
Malar rash
Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds.
Discoid rash
Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions.
Photosensitivity
Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation.
Oral ulcers
Oral or nasopharyngeal ulceration, usually painless, observed by physician.
Arthritis
Nonerosive arthritis involving ≥2 peripheral joints, characterized by tenderness, swelling, or effusion.
Serositis (one of the following):
Pleuritis: convincing history of pleuritic pain, pleural rubs on auscultation, or evidence of pleural effusion
Pericarditis: documented by ECG, pericardial rub, or evidence of pericardial effusion.
Renal disorder (one of the following):
Persistent proteinuria >0.5 g/day or >3+ if quantification not performed
Cellular casts: may be red cell, hemoglobin, granular, tubular, or mixed.
Neurologic disorder (one of the following):
Seizures: in the absence of offending drugs or known metabolic derangements (e.g., uremia, ketoacidosis, or electrolyte imbalance)
Psychosis: in the absence of offending drugs or known metabolic derangements (e.g., uremia, ketoacidosis, or electrolyte imbalance).
Hematologic disorder (one of the following):
Hemolytic anemia: with reticulocytes
Leukopenia: <4000/mm³ on ≥2 occasions
Lymphopenia: <1500/mm³ on ≥2 occasions
Thrombocytopenia: <100,000/mm³ in the absence of offending drugs.
Immunologic disorder (one of the following):
Anti-DNA: presence of antibody to native DNA in abnormal titer
Anti-Smith: presence of antibody to Smith nuclear antigen
Positive findings of antiphospholipid antibodies based on:
An abnormal serum level of IgG or IgM anticardiolipin antibodies
Positive test result for lupus anticoagulant using a standard method
A false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test.
Antinuclear antibody (ANA)
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with drug-induced lupus syndrome.
2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus[4]
The SLICC criteria for SLE classification requires:
Fulfillment of at least 4 criteria, with at least one clinical criterion AND one immunologic criterion
OR
Lupus nephritis as the sole clinical criterion in the presence of ANA or anti-dsDNA antibodies.
Clinical criteria:
Acute cutaneous lupus
Chronic cutaneous lupus
Oral ulcers: palate
Nonscarring alopecia (diffuse thinning or hair fragility with visible broken hairs)
Synovitis involving two or more joints, characterized by swelling or effusion OR tenderness in two or more joints and 30 minutes or more of morning stiffness
Serositis
Renal
Neurologic
Hemolytic anemia
Leukopenia (<4000/mm³ at least once)
Thrombocytopenia (<100,000/mm³) at least once.
Immunologic criteria:
ANA above laboratory reference range
Anti-dsDNA above laboratory reference range, except enzyme-linked immunosorbent assay: twice above laboratory reference range
Anti-Smith
Antiphospholipid antibody: any of the following
Low complement
Direct Coombs test in the absence of hemolytic anemia.
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices[5]
Class I: minimal mesangial lupus nephritis
Class II: mesangial proliferative lupus nephritis
Class III: focal lupus nephritis
Class III (A): active lesions - focal proliferative lupus nephritis
Class III (A/C):
Active and chronic lesions: focal proliferative and sclerosing lupus nephritis class III (C)
Chronic inactive lesions: focal sclerosing lupus nephritis
Class IV: diffuse lupus nephritis
Class V: membranous lupus nephritis
Class VI: advanced sclerosis lupus nephritis.
Use of this content is subject to our disclaimer